NHS England has called on the Association of British Neurologists to draw up interim guidance on the use of cannabis-based products for medical use in adult neurological conditions, including multiple sclerosis.
The regulatory group said prescribers would be advised to adopt the resultant guidelines, but to use existing provisional guidance at least until National Institute for Care and Health Excellence (NICE) guidelines are released in Oct 2019.
Prescribers are also advised to consult their local hospital chief pharmacist or director of pharmacy.
See more in The Pharmaceutical Journal - pharmaceutical-journal.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 Nov 18
